ARRIVENT BIOPHARMA, INC. Increase Decrease In Operating Lease Liability
ARRIVENT BIOPHARMA, INC. (AVBP) reported Increase Decrease In Operating Lease Liability of -$20.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-12
- ARRIVENT BIOPHARMA, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$67.00K.
- ARRIVENT BIOPHARMA, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was $47.00K.
- ARRIVENT BIOPHARMA, INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$5.00K.
- ARRIVENT BIOPHARMA, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$6.00K.
- ARRIVENT BIOPHARMA, INC. increase decrease in operating lease liability for fiscal 2025 was -$21.00K.
- ARRIVENT BIOPHARMA, INC. increase decrease in operating lease liability for fiscal 2024 was -$2.00K, a 108.00% decline from fiscal 2023.
- ARRIVENT BIOPHARMA, INC. increase decrease in operating lease liability for fiscal 2023 was $25.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$67.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$20.00K 10-Q · filed 2026-08-12 | -$25.00K derived: sum of 3 quarters · filed 2026-08-12 | -$31.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $47.00K 10-Q · filed 2026-05-11 | $42.00K derived: sum of 2 quarters · filed 2026-05-11 | $36.00K derived: sum of 3 quarters · filed 2026-05-11 | $30.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$11.00K derived: sum of 2 quarters · filed 2026-03-05 | -$17.00K derived: sum of 3 quarters · filed 2026-08-12 | -$21.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | -$6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$12.00K derived: sum of 2 quarters · filed 2026-08-12 | -$16.00K 10-Q · filed 2025-11-10 | -$20.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$10.00K 10-Q · filed 2026-08-12 | -$14.00K derived: sum of 3 quarters · filed 2026-08-12 | -$18.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$4.00K 10-Q · filed 2026-05-11 | -$8.00K derived: sum of 2 quarters · filed 2026-05-11 | -$12.00K derived: sum of 3 quarters · filed 2026-05-11 | -$16.00K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$8.00K derived: sum of 2 quarters · filed 2026-03-05 | -$12.00K derived: sum of 3 quarters · filed 2026-03-05 | -$2.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | -$4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$8.00K derived: sum of 2 quarters · filed 2025-11-10 | $2.00K 10-Q · filed 2025-11-10 | |
| 2024-06-30 | -$4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $6.00K 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $10.00K 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $25.00K 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |